Heghine Khachatryan: Efgartigimod Shows Promising Results in iTTP
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared a post on LinkedIn:
“One of the most anticipated sessions at ISTH 2026 focused on the evolving treatment landscape of immune thrombocytopenia (ITP), highlighting the Phase III ADVANCE IV program evaluating intravenous efgartigimod, an FcRn antagonist that selectively reduces pathogenic IgG autoantibodies while preserving broader immune function.
The updated results demonstrated that efgartigimod achieved rapid and clinically meaningful platelet recovery, with responses observed as early as the first week of treatment and significantly higher rates of sustained platelet responses compared with placebo. By Day 42, a substantially greater proportion of patients achieved both platelet counts ≥100×10⁹/L and International Working Group (IWG) responses, supporting a fast onset of action and durable clinical benefit.
Equally important, the safety profile remained favorable. Treatment was generally well tolerated, with most adverse events classified as mild to moderate, reinforcing the therapeutic potential of FcRn inhibition for patients with persistent and chronic ITP.
These data represent another important step toward precision immunotherapy in ITP, shifting management beyond symptomatic platelet support to targeted modulation of the autoimmune mechanisms responsible for platelet destruction.
Such advances continue to redefine expectations for efficacy, durability, and quality of life in patients living with chronic immune thrombocytopenia.”
Stay Updated with the Latest ISTH 2026 Updates on Hemostasis Today.
-
Oct 17, 2026, 12:21Jalen Hurts Sidelined by a Superficial Blood Clot: What to Know
-
Oct 17, 2026, 09:33Robert Lookstein: Mechanical Thrombectomy Shows Functional Benefits in Intermediate-High-Risk PE
-
Oct 17, 2026, 09:18Sarra Hmidi: Tunisia Highlights Thrombosis Prevention on World Thrombosis Day
-
Oct 17, 2026, 09:05Addressing the Hidden Burden of Bleeding Disorders in Women – Hemophilia Society Mumbai Chapter
-
Oct 17, 2026, 08:49Maria Magnusson: Karolinska Experts Explore Gene Therapy in Sickle Cell Disease and Hemophilia
-
Oct 17, 2026, 04:07Weihao Li: Global HEPATIC Registry Findings on Post-Transplant Arterial Thrombosis
-
Oct 17, 2026, 03:56Ghaith Abu-Zeinah: ASH Publishes 2026 Guidelines for Myelofibrosis Management in Blood Advances
-
Oct 17, 2026, 03:48Tristan Siokos: Why Vascular Occlusion Is More Than Just Clots – Breakdown of the 8 Pathways
-
Oct 17, 2026, 02:36Archil Jaliashvili: Oxygen Transport in Capillaries